Among various CCR2 inhibitors, the effect of Cenicriviroc, a CCR2/CCR5 co-inhibitor, is verified in the phase II clinical trial of 289 patients with nonalcoholic steatohepatitis and liver fibrosis. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.